1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

摘要: To evaluate the efficacy and safety of half-dose photodynamic therapy (PDT combined with ranibizumab for polypoidal choroidal vasculopathy (PCV). PCV is commonly treated a combination anti-vascular endothelial growth factor standard-dose (PDT). Choroidal ischemia visual loss can be resulted from PDT. Half-dose PDT has proved to produce similar results profile in treating central serous chorioretinopathy. may offer an alternative cases where damage vasculature maybe less. Here, we report In this prospective, non-comparative, interventional case series, 19 treatment-naive eyes were ranibizumab. All subjects followed up 12 months measurement best-corrected acuity (BCVA), foveal thickness (CFT) by optical coherence tomography. Indocyanine green angiogram (ICG) was performed every 3-monthly, assessed terms polyp regression rates, changes vision thickness, need repeat Subgroup analysis based on ICG features. The mean logMAR BCVA improved 0.64 at baseline 0.41 months. CFT 459.6mum 384.2mum difference between that statistically significant (both P = 0.03). Polyp rate after one 42.1 %. This 61.5 % polyp-only group, while branching-vascular-network (BVN) group 0 (P = <0.01). intravitreal able induce high had single polyp.